Cited by 318Peripheral Artery Disease ManagementLipoproteins and Cardiovascular HealthAntiplatelet Therapy and Cardiovascular Diseases

Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry

Open access
Kumbhani, Dharam J., Steg, Ph. Gabriel, Cannon, Christopher P., Eagle, Kim A., Smith, Sidney C., Goto, Shinya, Ohman, E. Magnus, Elbez, Yedid +5 more·2014·European Heart Journal

Abstract

AIMS: Due to a high burden of systemic cardiovascular events, current guidelines recommend the use of statins in all patients with peripheral artery disease (PAD). We sought to study the impact of statin use on limb prognosis in patients with symptomatic PAD enrolled in the international REACH registry. METHODS: Statin use was assessed at study enrolment, as well as a time-varying covariate. Rates of the primary adverse limb outcome (worsening claudication/new episode of critical limb ischaemia, new percutaneous/surgical revascularization, or amputation) at 4 years and the composite of cardiovascular death/myocardial infarction/stroke were compared among statin users vs. non-users. RESULTS: A total of 5861 patients with symptomatic PAD were included. Statin use at baseline was 62.2%. Patients who were on statins had a significantly lower risk of the primary adverse limb outcome at 4 years when compared with those who were not taking statins [22.0 vs. 26.2%; hazard ratio (HR), 0.82; 95% confidence interval (CI), 0.72-0.92; P = 0.0013]. Results were similar when statin use was considered as a time-dependent variable (P = 0.018) and on propensity analysis (P < 0.0001). The composite of cardiovascular death/myocardial infarction/stroke was similarly reduced (HR, 0.83; 95% CI, 0.73-0.96; P = 0.01). CONCLUSION: Among patients with PAD in the REACH registry, statin use was associated with an ∼18% lower rate of adverse limb outcomes, including worsening symptoms, peripheral revascularization, and ischaemic amputations. These findings suggest that statin therapy not only reduces the risk of adverse cardiovascular events, but also favourably affects limb prognosis in patients with PAD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehu080

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In the REACH registry, statin use was associated with about an 18% lower rate of adverse limb outcomes.

    “in the Reduction of Atherothrombosis for Continued Health (REACH) registry, statin use was associated with an ~18% lower rate of adverse limb outcomes.408”

    From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [408]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kumbhani, D. J., Steg, P. G., Cannon, C. P., Eagle, K. A., Smith, S. C., Goto, S., Ohman, E. M., Elbez, Y., Sritara, P., Baumgartner, I., Banerjee, S., Creager, M. A., & Bhatt, D. L.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • Brigham and Women's Hospital (US)
  • University of Michigan (US)
  • University of North Carolina at Chapel Hill (US)
  • Tokai University (JP)
  • Duke University (US)
  • Inserm (FR)
  • Mahidol University (TH)
Corresponding author
Kumbhani, Dharam J.
Venue
European Heart Journal
Published
2014-02-28
Volume
35
Issue
41
Pages
2864-2872
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2160694670
Cited by
318
References
42
Citations by year
2026: 12 · 2025: 24 · 2024: 22 · 2023: 19 · 2022: 28 · 2021: 40 · 2020: 36 · 2019: 26 · 2018: 38 · 2017: 27 · 2016: 25 · 2015: 14 · 2014: 6 · 2013: 1
FWCI
23.76
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • reroDoc Digital Library (submittedVersion)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Keywords
statin therapy, peripheral arterial disease, critical limb ischemia, amputation, revascularization, claudication, cardiovascular events, REACH registry
MeSH terms
Aged, Coronary Artery Disease, Extremities, Female, Humans, Intermittent Claudication, Ischemia, Male, Physician's Role, Registries, Treatment Outcome, Disease Progression, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Peripheral Arterial Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review